Luke Boulter

Luke Boulter

Auto-generated profile, based on publicly available information

Luke Boulter

MRC Human Genetics Unit, Institute of Genetics and Cancer, Edinburgh, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2020 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Open access
PDF file
Jesús BañalesJesús Bañales
Jesús Bañales
Jose MarinJose Marin
Jose Marin
ALAngela Lamarca
Angela Lamarca
Cecilia MP RodrigugesCecilia MP Rodriguges
Cecilia MP Rodriguges
SKShahid A Khan
Shahid A Khan
GGGregory J. Gores
Gregory J. Gores
Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for ~15% of all primary liver cancers and ~3% of gastrointestinal malignancies. The silent presentation of these tumours combined with their highly aggressive nature and refractoriness to chemotherapy contribute to their alarming mortality, representing ~2% of all cancer-related deaths worldwide yearly. The current diagnosis of CCA by non-invasive approaches is not accurate enough, and histological confirmation is necessary. Furthermore, the high heterogeneity of CCAs at the genomic, epigenetic and molecular levels severely compromises the efficacy of the available therapies. In the past decade, increasing efforts have been made to understand the complexity of these tumours and to develop new diagnostic tools and therapies that might help to improve patient outcomes. In this expert Consensus Statement, which is endorsed by the European Network for the Study of Cholangiocarcinoma, we aim to summarize and critically discuss the latest advances in CCA, mostly focusing on classification, cells of origin, genetic and epigenetic abnormalities, molecular alterations, biomarker discovery and treatments. Furthermore, the horizon of CCA for the next decade from 2020 onwards is highlighted.

18 April 2016 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
LPLara Planas-Paz
Lara Planas-Paz
VOVanessa Orsini
Vanessa Orsini
LBLuke Boulter
Luke Boulter
DCDiego Calabrese
Diego Calabrese
MPMonika Pikiolek
Monika Pikiolek
JTJan S. Tchorz
Jan S. Tchorz

15 August 2018 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
TBThomas G. Bird
Thomas G. Bird
MMMiryam Müller
Miryam Müller
LBLuke Boulter
Luke Boulter
DVDavid F. Vincent
David F. Vincent
RRRachel A. Ridgway
Rachel A. Ridgway
SFStuart J. Forbes
Stuart J. Forbes
Inhibiting acute injury–induced senescence mediated by TGFβ signaling in regenerative epithelium improves liver regeneration.

1 June 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
PHPriya Hari
Priya Hari
FMFraser R. Millar
Fraser R. Millar
NTNuria Tarrats
Nuria Tarrats
JBJodie Birch
Jodie Birch
AQAndrea Quintanilla
Andrea Quintanilla
JAJuan Carlos Acosta
Juan Carlos Acosta
Cellular senescence is a stress response program characterized by a robust cell cycle arrest and the induction of a proinflammatory senescence-associated secretory phenotype (SASP) that is triggered through an unknown mechanism. Here, we show that, during oncogene-induced senescence (OIS), the Toll-like receptor 2 (TLR2) and its partner TLR10 are key mediators of senescence in vitro and in murine models. TLR2 promotes cell cycle arrest by regulating the tumor suppressors p53-p21CIP1, p16INK4a, and p15INK4b and regulates the SASP through the induction of the acute-phase serum amyloids A1 and A2 (A-SAAs) that, in turn, function as the damage-associated molecular patterns (DAMPs) signaling through TLR2 in OIS. Last, we found evidence that the cGAS-STING cytosolic DNA sensing pathway primes TLR2 and A-SAAs expression in OIS. In summary, we report that innate immune sensing of senescence-associated DAMPs by TLR2 controls the SASP and reinforces the cell cycle arrest program in OIS.

9 March 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
SFSofia Ferreira-Gonzalez
Sofia Ferreira-Gonzalez
WLWei-Yu Lu
Wei-Yu Lu
ARAlexander Raven
Alexander Raven
BDBenjamin Dwyer
Benjamin Dwyer
TMTak Yung Man
Tak Yung Man
SFStuart J. Forbes
Stuart J. Forbes
Cellular senescence is a mechanism that provides an irreversible barrier to cell cycle progression to prevent undesired proliferation. However, under pathological circumstances, senescence can adversely affect organ function, viability and regeneration. We have developed a mouse model of biliary senescence, based on the conditional deletion of Mdm2 in bile ducts under the control of the Krt19 promoter, that exhibits features of biliary disease. Here we report that senescent cholangiocytes induce profound alterations in the cellular and signalling microenvironment, with recruitment of myofibroblasts and macrophages causing collagen deposition, TGFβ production and induction of senescence in surrounding cholangiocytes and hepatocytes. Finally, we study how inhibition of TGFβ-signalling disrupts the transmission of senescence and restores liver function. We identify cellular senescence as a detrimental mechanism in the development of biliary injury. Our results identify TGFβ as a potential therapeutic target to limit senescence-dependent aggravation in human cholangiopathies.

10 December 2025 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Open access
PDF file
Jesús BañalesJesús Bañales
Jesús Bañales
Cecilia MP RodrigugesCecilia MP Rodriguges
Cecilia MP Rodriguges
SASilvia Affo
Silvia Affo
JAJesper B Andersen
Jesper B Andersen
PAPatricia Aspichueta
Patricia Aspichueta
CBChiara Braconi
Chiara Braconi
Cholangiocarcinoma (CCA) is a cancer that originates within the bile ducts. Traditionally considered to be a rare neoplasm, increased awareness of CCA alongside advancements in diagnosis and the rising prevalence of certain risk factors have contributed to a global increase in incidence and mortality. CCAs are highly heterogeneous from the clinical, histomorphological and molecular perspectives but commonly share a poor prognosis. These tumours usually develop and progress silently; by the time they are detected, it is often too late for curative surgical intervention. In such cases, current therapeutic approaches offer modest survival improvements and are generally considered palliative. Although well-known risk factors predispose individuals to developing CCA, the majority of cases are considered sporadic, occurring without any identifiable underlying condition. Over the past decade, substantial collaborative efforts have been made to improve our understanding of the aetiopathogenesis of these tumours, aiming to identify novel biomarkers and therapeutic targets to develop more effective treatments. The ultimate goal is to improve patient outcomes and overall well-being. However, there are significant gaps in our understanding of the molecular mechanisms that drive cholangiocarcinogenesis. In this international Consensus Statement, which is endorsed by the European Network for the Study of Cholangiocarcinoma, we provide a critical overview of the latest advancements in the field of CCA. We highlight the key aspects of CCA aetiopathogenesis and clinical management and provide insights into promising new treatments. Finally, we provide a set of consensus recommendations and future research priorities for CCA based on a Delphi panel questionnaire involving international experts.